Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18258603 | 1.00 | NPSR1 (0.55) | NPSR1HSD17B10PPARGMAPTTP53 | |
| SCHEMBL5512388 | 0.83 | NPSR1 (0.52) | NPSR1HSD17B10PPARGMAPTTP53 | |
| SCHEMBL18258632 | 0.83 | NPSR1 (0.52) | NPSR1HSD17B10PPARGMAPTTP53 | |
| SCHEMBL18258597 | 0.82 | NPSR1 (0.47) | NPSR1HSD17B10PPARGMAPTTP53 | |
| SCHEMBL18258598 | 0.82 | NPSR1 (0.47) | NPSR1HSD17B10PPARGMAPTTP53 | |
| SCHEMBL3050045 | 0.80 | CA1 (0.42) | NPSR1HSD17B10PPARGMAPTTP53 | |
| SCHEMBL18258589 | 0.79 | NPSR1 (0.49) | NPSR1HSD17B10PPARGMAPTTP53 | |
| SCHEMBL18258587 | 0.79 | NPSR1 (0.49) | NPSR1HSD17B10PPARGMAPTTP53 | |
| SCHEMBL29180304 | 0.79 | NPSR1 (0.57) | NPSR1HSD17B10PPARGMAPTTP53 | |
| SCHEMBL2793671 | 0.79 | NPSR1 (0.57) | NPSR1HSD17B10PPARGMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119265552-A | Chemical nickel-plating palladium-gold solution | 生益电子股份有限公司 | 2025-01-07 | — | — | CN | claimed |
| CN-118185522-A | Adhesive, preparation method and application thereof in lithium battery electrode | 常熟市辐照技术应用厂 | 2024-06-14 | — | — | CN | claimed |
| CN-119265552-A | Chemical nickel-plating palladium-gold solution | 生益电子股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-118185522-A | Adhesive, preparation method and application thereof in lithium battery electrode | 常熟市辐照技术应用厂 | 2024-06-14 | — | — | CN | disclosed |
| CN-118185522-A | Adhesive, preparation method and application thereof in lithium battery electrode | 常熟市辐照技术应用厂 | 2024-06-14 | — | — | CN | disclosed |
| CN-114217505-A | Photoresist, display substrate and display panel | 长沙惠科光电有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-10987408-B2 | Compositions and methods for modulating toll-like receptor 2 activation | THE CLEVELAND CLINIC FOUNDATION (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190069527-A1 | MOUSE MODEL OF RETINAL DEGENERATION | CLEVELAND CLINIC FOUNDATION | 2019-03-07 | — | — | US | disclosed |
| US-20180280482-A1 | COMPOSITIONS AND METHODS FOR MODULATING TOLL-LIKE RECEPTOR 2 ACTIVATION | CLEVELAND CLINIC FOUND (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180160660-A1 | MOUSE MODEL OF RETINAL DEGENERATION | CLEVELAND CLINIC FOUNDATION | 2018-06-14 | — | — | US | disclosed |
| US-9981018-B2 | Compositions and methods for modulating toll-like receptor 2 activation | THE CLEVELAND CLINIC FOUNDATION (US) | 2018-05-29 | — | — | US | disclosed |
| WO-2008089487-A2 | CARBOXYETHYLPYRROLE COMPOUNDS AND METHODS OF THEIR PRODUCTION | THE CLEVELAND CLINIC FOUNDATION (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2007127151-A2 | NON-HUMAN MODEL OF AUTOIMMUNE DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2007-11-08 | — | — | WO | disclosed |
| EP-1451376-A2 | A COATED FILM LAMINATE HAVING AN ELECTRICALLY CONDUCTIVE SURFACE | 3M Innovative Properties Company (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040115793-A1 | COATED FILM LAMINATE HAVING AN ELECTRICALLY CONDUCTIVE SURFACE | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-17 | — | — | US | disclosed |
| WO-2003106962-A2 | A COATED FILM LAMINATE HAVING AN ELECTRICALLY CONDUCTIVE SURFACE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-12-24 | — | — | WO | disclosed |
| EP-0887353-B1 | Luminescence indicator | HOFFMANN LA ROCHE (CH) | 2003-08-20 | — | — | EP | disclosed |
| US-5981746-A | Luminescence indicator | AVL MEDICAL INSTRUMENTS (CH) | 1999-11-09 | — | — | US | disclosed |
| EP-0887353-A2 | Luminescence indicator | AVL Medical Instruments (CH) | 1998-12-30 | — | — | EP | disclosed |
| US-4148998-A | ANTIBIOTICS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1979-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987408-B2 | Compositions and methods for modulating toll-like receptor 2 activation | TLR2, TLR3, TLR1 | NPSR1 484/4885HSD17B10 2405/4885PPARG 270/4885 |
| US-20180280482-A1 | COMPOSITIONS AND METHODS FOR MODULATING TOLL-LIKE RECEPTOR 2 ACTIVATION | TLR2, TLR3, TLR1 | NPSR1 484/4885HSD17B10 2405/4885PPARG 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.